{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromatosis+Type+1-Associated+Plexiform+Neurofibromas",
    "query": {
      "condition": "Neurofibromatosis Type 1-Associated Plexiform Neurofibromas"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T21:58:16.839Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05028166",
      "title": "Individual Patient Compassionate Use of Mirdametinib",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Neurofibromatosis Type 1-Associated Plexiform Neurofibromas",
        "Histiocytic Neoplasm",
        "Other MAP-K Pathway Driven Diseases"
      ],
      "interventions": [
        {
          "name": "Mirdametinib (MEK Inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-08T21:58:16.839Z",
      "location_count": 1,
      "location_summary": "Billerica, Massachusetts",
      "locations": [
        {
          "city": "Billerica",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028166"
    },
    {
      "nct_id": "NCT02390752",
      "title": "Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neurofibroma, Plexiform",
        "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
        "Leukemia, Promyelocytic, Acute",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "TURALIO(R)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "3 Years to 35 Years"
      },
      "enrollment_count": 54,
      "start_date": "2015-04-29",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-08T21:58:16.839Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02390752"
    },
    {
      "nct_id": "NCT02096471",
      "title": "MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN"
      ],
      "interventions": [
        {
          "name": "PD-0325901",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2014-06",
      "completion_date": "2018-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-10-08T21:58:16.839Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096471"
    },
    {
      "nct_id": "NCT03231306",
      "title": "Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 1",
        "Plexiform Neurofibroma"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 45,
      "start_date": "2017-11-28",
      "completion_date": "2024-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-10-08T21:58:16.839Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03231306"
    },
    {
      "nct_id": "NCT03962543",
      "title": "MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plexiform Neurofibroma",
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "Mirdametinib (PD-0325901) oral capsule or dispersible tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2019-09-29",
      "completion_date": "2028-12-22",
      "has_results": true,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-08T21:58:16.839Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03962543"
    }
  ]
}